Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Soligenix Inc SNGX

Healthcare Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SNGX)

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire May 4, 2023

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

PR Newswire May 3, 2023

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

PR Newswire May 1, 2023

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire April 24, 2023

Soligenix Provides Regulatory Update on HyBryte(TM)

PR Newswire April 14, 2023

Soligenix Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte(TM) and SGX302

PR Newswire April 5, 2023

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire April 3, 2023

Soligenix Announces Recent Accomplishments And Year-End 2022 Financial Results

PR Newswire March 31, 2023

Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire March 9, 2023

Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire February 14, 2023

Soligenix Announces Reverse Stock Split

PR Newswire February 9, 2023

Soligenix Invited to Present at the Virtual Investor Summit Event

PR Newswire January 19, 2023

Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

PR Newswire December 23, 2022

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge

PR Newswire December 20, 2022

Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis

PR Newswire December 19, 2022

Soligenix Announces Submission of New Drug Application to the FDA for HyBryte(TM) in the Treatment of Cutaneous T-cell Lymphoma

PR Newswire December 15, 2022

Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

PR Newswire November 15, 2022

Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference

Newsfile November 11, 2022

Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results

PR Newswire November 10, 2022

Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses

PR Newswire October 27, 2022